
Novartis preps a 2020 launch in multiple sclerosis as 2 successful pivotal trials set stage for an assault on Roche’s new star franchise
Novartis’ Arzerra appears ready to grab a new lease on blockbuster life as the Swiss pharma giant rolls out its top-line snapshot this morning on 2 successful head-to-head studies in multiple sclerosis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.